“We expect to see vaccinations continue in October through December.”

In context

“st before that wave declined. And we've built a very durable commercial engine to support that with increasing treatment rates, with very viable reimbursement, both on the government side as well as on the commercial side and a way to activate HCPs and consumers who need our treatment. And similarly, on the vaccine, our goal this year with COMIRNATY, and we had the benefit of being able to start 3 weeks before last year, was to start the season with plenty of vaccine in fridges, both in the retail setting as well as in the health system setting. And again, we've demonstrated an ability to do that quite well. When you look at where vaccination is this year versus last year, it's a little bit higher, actually, but a big part of that is just a function of the calendar in the 3 weeks earlier. We expect to see vaccinations continue in October through December. And the shape of that curve will continue to evolve, but all of this makes us confident that we're seeing a durable business, both on vaccines and PAX. Alexandre de Germay: For international, this is Alexandre, thanks for the question, too. Same principles, we see enduring business. In COMIRNATY, just I want to remind everyone that in the International vision, we closed our third quarter at the end of August. So basically, you don't see any sales of COMIRNATY simply because most markets are starting of the vaccination campaign in September. Having said that, we are progressing very nicely in our key regions. So in Europe, we got the approval of the GEN-1 adapted vaccine in July, and we got the KP12 [indiscernible] September. So it's basically an [indiscernible] started to work with our he”